Anil Kumar
Research Subjects
Anil Kumar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Divakar Sharma
Department of Biotechnology Graphic Era (Deemed to be) University Dehradun India
4 shared publications - Indu Singh
School of Pharmacy Graphic Era Hill University Dehradun India
4 shared publications - Anushri Keshri
Department of Biotechnology Holy Cross Women's College Ambikapur Chhattisgarh India
2 shared publications - Arun Kumar
Department of Biotechnology School of Basic and Applied Sciences Shri Guru Ram Rai University Dehradun India
2 shared publications - Arun Ratn
Sanatan Dharm College
2 shared publications - Awdhesh Kumar Chaudhary
Rachit Multispeciality Hospital
2 shared publications
Latest Publications
- 26 May 2026
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 27
Hijacking of GPCRs and angiotensin-converting enzyme-2 in the pathophysiology of infectious diseases
Introduction: Infectious diseases caused by pathogens have posed health concerns worldwide since ancient times, and the development of preventive approaches has been a focus. Pathogens establish infections by targeting particular host protein receptors, such as angiotensin-converting enzyme-2 (ACE2), membrane-anchored proteins, or signaling components like G-protein-coupled receptors (GPCRs), through interactions or by modulating host proteins via secreted toxic compounds. GPCRs are broadly distributed receptors regulating multiple physiological activities, from neurotransmitter feedback and environmental triggers to hormonal feedback. Innumerable pathogens target 100 of the GPCRs in different ways to evade immune responses, survival, and virulence. Method: For the synthesis of this review, the literature was searched in databases by using the search engines (like PubMed, SCOPUS, Web of Sciences, ScienceDirect, Google Scholar, etc.), and the following keywords: “Infectious Diseases, G-protein coupled receptors (GPCRs), angiotensin converting enzyme-2 (ACE-2), Pathophysiology, Renin-angiotensin-aldosterone system (RAAS)” were used. Conclusions: This focused review emphasizes the roles of GPCR and ACE2 receptors in the RAAS, pathophysiology of infectious diseases, and their impact on these receptor-mediated downstream signaling pathways. The current article also discussed the impact of GPCRs and ACE2 receptors on pathogenicity and host cellular responses, and on improving our knowledge of host-pathogen interactions at the molecular and cellular levels; therefore, it might open avenues for novel therapeutic agents and preventive approaches.
- 26 May 2026
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 27
Hijacking of GPCRs and angiotensin-converting enzyme-2 in the pathophysiology of infectious diseases
Introduction: Infectious diseases caused by pathogens have posed health concerns worldwide since ancient times, and the development of preventive approaches has been a focus. Pathogens establish infections by targeting particular host protein receptors, such as angiotensin-converting enzyme-2 (ACE2), membrane-anchored proteins, or signaling components like G-protein-coupled receptors (GPCRs), through interactions or by modulating host proteins via secreted toxic compounds. GPCRs are broadly distributed receptors regulating multiple physiological activities, from neurotransmitter feedback and environmental triggers to hormonal feedback. Innumerable pathogens target 100 of the GPCRs in different ways to evade immune responses, survival, and virulence. Method: For the synthesis of this review, the literature was searched in databases by using the search engines (like PubMed, SCOPUS, Web of Sciences, ScienceDirect, Google Scholar, etc.), and the following keywords: “Infectious Diseases, G-protein coupled receptors (GPCRs), angiotensin converting enzyme-2 (ACE-2), Pathophysiology, Renin-angiotensin-aldosterone system (RAAS)” were used. Conclusions: This focused review emphasizes the roles of GPCR and ACE2 receptors in the RAAS, pathophysiology of infectious diseases, and their impact on these receptor-mediated downstream signaling pathways. The current article also discussed the impact of GPCRs and ACE2 receptors on pathogenicity and host cellular responses, and on improving our knowledge of host-pathogen interactions at the molecular and cellular levels; therefore, it might open avenues for novel therapeutic agents and preventive approaches.
- 1 March 2026
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 27
Adeno-associated virus (AAV) mediated advanced therapeutic interventions for inherited and non-inherited cardiac disorders
Introduction: Cardiovascular diseases remain the leading cause of global morbidity and mortality, driven by a complex interplay of inherited and acquired factors that limit the long-term effectiveness of conventional pharmacological, surgical, and device-based therapies. Recent advances in gene therapy have positioned adeno-associated virus (AAV) vectors as a promising platform for addressing the molecular determinants of both inherited and non-inherited cardiac disorders. Owing to their favourable safety profile, low pathogenicity, sustained transgene expression, and broad tissue tropism, AAV vectors have evolved as the most comprehensively evaluated viral delivery system in cardiovascular gene therapy. Method: This classical review was compiled after a comprehensive literature search of major scientific databases, including PubMed, Scopus, and Web of Science, using keywords related to adeno-associated virus, therapies, inherited and non-inherited cardiac disorders. This review provides a comprehensive synthesis of the biological properties of AAV vectors, with emphasis on serotype-specific cardiac tropism, receptor usage, immunogenicity, and durability of gene expression. We critically assess preclinical and clinical evidence supporting AAV-mediated gene delivery across a spectrum of cardiac conditions, including heart failure, cardiomyopathies, ischemic heart disease, and inherited arrhythmias, highlighting both therapeutic successes and translational limitations. Conclusions: This review highlights the current delivery strategies, genetic cargoes, and emerging genome-editing approaches, which are discussed in the context of efficacy and safety. Key challenges-such as pre-existing immunity, dose-dependent toxicity, off-target transduction, manufacturing scalability, regulatory constraints, and clinical trial design-are analysed to delineate barriers to widespread clinical adoption. Finally, we outline future directions focused on rational capsid engineering, tissue-specific targeting, improved manufacturing pipelines, and optimized clinical strategies required to advance AAV-based gene therapy toward durable and accessible treatments for cardiac diseases.
- 1 March 2026
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 27
Adeno-associated virus (AAV) mediated advanced therapeutic interventions for inherited and non-inherited cardiac disorders
Introduction: Cardiovascular diseases remain the leading cause of global morbidity and mortality, driven by a complex interplay of inherited and acquired factors that limit the long-term effectiveness of conventional pharmacological, surgical, and device-based therapies. Recent advances in gene therapy have positioned adeno-associated virus (AAV) vectors as a promising platform for addressing the molecular determinants of both inherited and non-inherited cardiac disorders. Owing to their favourable safety profile, low pathogenicity, sustained transgene expression, and broad tissue tropism, AAV vectors have evolved as the most comprehensively evaluated viral delivery system in cardiovascular gene therapy. Method: This classical review was compiled after a comprehensive literature search of major scientific databases, including PubMed, Scopus, and Web of Science, using keywords related to adeno-associated virus, therapies, inherited and non-inherited cardiac disorders. This review provides a comprehensive synthesis of the biological properties of AAV vectors, with emphasis on serotype-specific cardiac tropism, receptor usage, immunogenicity, and durability of gene expression. We critically assess preclinical and clinical evidence supporting AAV-mediated gene delivery across a spectrum of cardiac conditions, including heart failure, cardiomyopathies, ischemic heart disease, and inherited arrhythmias, highlighting both therapeutic successes and translational limitations. Conclusions: This review highlights the current delivery strategies, genetic cargoes, and emerging genome-editing approaches, which are discussed in the context of efficacy and safety. Key challenges-such as pre-existing immunity, dose-dependent toxicity, off-target transduction, manufacturing scalability, regulatory constraints, and clinical trial design-are analysed to delineate barriers to widespread clinical adoption. Finally, we outline future directions focused on rational capsid engineering, tissue-specific targeting, improved manufacturing pipelines, and optimized clinical strategies required to advance AAV-based gene therapy toward durable and accessible treatments for cardiac diseases.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1)
Coagulase‐Negative Staphylococci (CoNS): An Emerging Threat, Antimicrobial Resistance, and Health Concern
Coagulase‐negative staphylococci (CoNS) have evolved from a harmless commensal group to an alarming threat to patient, environmental, and population health due to their challenging treatment and their impact on health outcomes. The widespread presence of CoNS in these environments poses a public health concern due to various virulence factors, biofilm formation, and toxin production, which contribute to pathogenicity and antimicrobial resistance (AMR). Major clinical manifestations include device‐related infections, bloodstream infections, and neonatal sepsis. Nonclinical reservoirs, such as soil, water, animals, and food‐processing environments, are considered critical sources of resistance gene flow. The mechanisms of resistance include the mecA gene and a variety of SCCmec elements, as well as horizontal gene transfer via plasmids and transposons, and tolerance via biofilm formation. This review summarizes current findings on the epidemiology, AMR mechanisms, biofilm‐linked pathogenicity, diagnostic advances, and One Health implementations of CoNS across nonclinical and clinical contexts, while recognizing priorities for therapeutic and surveillance development. Here, the reviewed literature suggests considerable variation in drug resistant CoNS and distribution landscapes across nonclinical and clinical contexts, with MGEs, biofilm establishment, and environmental repertoires reflecting imperative determinants in the dissemination and persistence of AMR. An analysis of the existing literature indicates that genetic links between clinical and environmental isolates remain insufficiently established and that surveillance data are lacking; accordingly, future research should focus on these gaps. Addressing the threat of CoNS requires enhanced surveillance, improved diagnostic precision, and the development of novel antimicrobial and antibiofilm strategies. Future research should focus on epidemiological surveillance, innovation in therapy, and systems‐based approaches, which consider the interrelationship of human, animal, and environmental health.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1)
Open AccessCoagulase‐Negative Staphylococci (CoNS): An Emerging Threat, Antimicrobial Resistance, and Health Concern
Coagulase‐negative staphylococci (CoNS) have evolved from a harmless commensal group to an alarming threat to patient, environmental, and population health due to their challenging treatment and their impact on health outcomes. The widespread presence of CoNS in these environments poses a public health concern due to various virulence factors, biofilm formation, and toxin production, which contribute to pathogenicity and antimicrobial resistance (AMR). Major clinical manifestations include device‐related infections, bloodstream infections, and neonatal sepsis. Nonclinical reservoirs, such as soil, water, animals, and food‐processing environments, are considered critical sources of resistance gene flow. The mechanisms of resistance include the mecA gene and a variety of SCCmec elements, as well as horizontal gene transfer via plasmids and transposons, and tolerance via biofilm formation. This review summarizes current findings on the epidemiology, AMR mechanisms, biofilm‐linked pathogenicity, diagnostic advances, and One Health implementations of CoNS across nonclinical and clinical contexts, while recognizing priorities for therapeutic and surveillance development. Here, the reviewed literature suggests considerable variation in drug resistant CoNS and distribution landscapes across nonclinical and clinical contexts, with MGEs, biofilm establishment, and environmental repertoires reflecting imperative determinants in the dissemination and persistence of AMR. An analysis of the existing literature indicates that genetic links between clinical and environmental isolates remain insufficiently established and that surveillance data are lacking; accordingly, future research should focus on these gaps. Addressing the threat of CoNS requires enhanced surveillance, improved diagnostic precision, and the development of novel antimicrobial and antibiofilm strategies. Future research should focus on epidemiological surveillance, innovation in therapy, and systems‐based approaches, which consider the interrelationship of human, animal, and environmental health.
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2026 (1) , 8603173
Colistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies
The rapid development of colistin‐resistant bacteria is the biggest global health issue since colistin is referred to as a ‘last‐hope resource’ against life‐threatening infections caused by GNB (Gram‐negative bacteria). Injudicious and excessive colistin application in clinical, agricultural and veterinary practices, as well as plasmid‐mediated horizontal gene transfer and chromosomal mutation, commonly contribute to colistin resistance. The coexistence of the mcr ‐1 gene with mcr variants, other intrinsic genes and other mechanisms might provide additional resistance strength against colistin. To prevent the emergence of colistin‐resistant strains and preserve the therapeutic efficacy of existing antibiotics, we must expand our deep understanding of colistin‐resistant strains at the molecular level. This critical review discusses the mechanism of action, various bacterial resistance mechanisms, the presence of mcr genes in bacterial plasmids, hetero‐resistance, biofilm formation, the horizontal transfer or dispersion of colistin‐resistant genes and combating strategies. Our synthesis underscores the need for strategically aligning mechanistic knowledge with practical therapeutic solutions to combat escalating colistin resistance and inform future medical decision‐making and research planning.
- 1 January 2026
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2026 (1) , 8603173
Open AccessColistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies
The rapid development of colistin‐resistant bacteria is the biggest global health issue since colistin is referred to as a ‘last‐hope resource’ against life‐threatening infections caused by GNB (Gram‐negative bacteria). Injudicious and excessive colistin application in clinical, agricultural and veterinary practices, as well as plasmid‐mediated horizontal gene transfer and chromosomal mutation, commonly contribute to colistin resistance. The coexistence of the mcr ‐1 gene with mcr variants, other intrinsic genes and other mechanisms might provide additional resistance strength against colistin. To prevent the emergence of colistin‐resistant strains and preserve the therapeutic efficacy of existing antibiotics, we must expand our deep understanding of colistin‐resistant strains at the molecular level. This critical review discusses the mechanism of action, various bacterial resistance mechanisms, the presence of mcr genes in bacterial plasmids, hetero‐resistance, biofilm formation, the horizontal transfer or dispersion of colistin‐resistant genes and combating strategies. Our synthesis underscores the need for strategically aligning mechanistic knowledge with practical therapeutic solutions to combat escalating colistin resistance and inform future medical decision‐making and research planning.